Method of Enhancing KSHV LANA1 Immunogenicity
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsYuan Chang, Patrick S. Moore
Life of this patent
Estimating the term…
Abstract
An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein.
Claims26
A method of eliciting an immune response to KSHV LANA1 in a patient comprising introducing into a cell of the patient the ieLANA1 peptide of claim 23.
2-16. (canceled)
18-22. (canceled)
An immunologically-enhanced LANA1 polypeptide (“ieLANA1 polypeptide”) for eliciting a CTL immune response to LANA1, comprising a LANA1 amino acid sequence comprising one or more LANA1 T-cell epitopes, wherein the LANA1 amino acid sequence is modified to exhibit increased CTL immune response as compared to wild-type LANA1 protein.
(canceled)
31-34. (canceled)
37-38. (canceled)
A polypeptide other than full-length LANA1 protein, comprising at the N-terminal or C-terminal end of the polypeptide, or inserted within the polypeptide an amino acid sequence obtained from or derived from CR1 region of a LANA1 central repeat domain and having the capacity to inhibit CTL immune response as compared to the same polypeptide without the amino acid sequence.
(canceled)
48-50. (canceled)
Dependencies are inferred from the claim text.